Takeda Pharmaceutical Company Ltd. (TAK), Thursday announced financial results for 9-month period, reporting earnings of 211.1 billion yen, up 43.5 percent from last year's 147.1 billion yen.
On per share basis, earnings increased to 134 yen from 94 yen in the previous year, highlighting the continued advancement of the drug maker's Growth & Launch Products.
Revenue, for the period, rose to 3,528.2 billion yen from 3,212.9 billion yen in prior year.
Looking ahead, the Japanese company sees revenue of 4,590 billion yen for the full year 2024, compared to the previously estimated 4,480 billion yen.
For the year ending on March 31, Takeda estimates earnings of 118 billion yen, an increase of 73.5 percent from the previously expected 68 billion yen.
Concurrently, the company also announced the decision to appoint Julie Kim as the Chief Executive Officer, succeeding Christophe Weber, who plans to retire from the position in June 2026.
Kim currently serves as president of Takeda's U.S. business unit.
Takeda Pharmaceutical is also planning to buy back shares.
In the pre-market hours, Takeda's stock is trading at $13.78, up 3.53 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.